Development of a novel peptide inhibitor of subtilisin BPN'.
FEBS Open Bio
; 12(11): 2057-2064, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-2093221
ABSTRACT
Proteinaceous protease inhibitors can strongly and specifically inhibit cognate proteases, but their use as pharmaceuticals is limited by their size. As such, the development of effective protease peptide inhibitors would be beneficial for biochemical studies and drug discovery. In this study, we applied a phage display system to select subtilisin BPN'-binding peptides and evaluated their inhibitory activities against subtilisin BPN'. A 12mer peptide with an intramolecular disulfide bond inhibited subtilisin BPN' (Ki value of 13.0 nm). Further mutational analyses of the peptide resulted in the development of a short peptide inhibitor against subtilisin BPN' that showed high inhibitory activity and binding affinity (Ki value of 0.30 nm). This activity was found to be derived from the conformational rigidity caused by the intramolecular disulfide bond and the small residue at the P1' site and from the interaction of the P4 and P6' residues with subtilisin BPN'.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Peptides
/
Subtilisins
Type of study:
Experimental Studies
Language:
English
Journal:
FEBS Open Bio
Year:
2022
Document Type:
Article
Affiliation country:
2211-5463.13481
Similar
MEDLINE
...
LILACS
LIS